Status:
COMPLETED
Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease
Lead Sponsor:
University of Bern
Collaborating Sponsors:
University Hospital, Basel, Switzerland
University of Lausanne Hospitals
Conditions:
Crohn Disease
Eligibility:
All Genders
18-70 years
Brief Summary
Background Determining disease activity in IBD is sometimes difficult and, to be accurate, requires endoscopy. The serum marker CRP has not proven sufficiently valuable as a marker for IBD specific in...
Detailed Description
Background Background Like mannan-binding lectin (MBL), ficolins are important soluble receptors for microbial associated molecular patterns leading to the activation of the lectin pathway complement...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- known IBD
- endoscopy for clinical reasons
- enrolled in the Swiss IBD cohort study
- Exclusion Criteria
Exclusion
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT01473927
Start Date
October 1 2011
End Date
June 1 2013
Last Update
March 12 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastroenterology and Hepatology, Basel University Hospital
Basel, Canton of Basel-City, Switzerland, 4031
2
DCR, Gastroenterology, Bern, University of Bern
Bern, Canton of Bern, Switzerland, 3010
3
Service de gastro-entérologie et hépatologie, CHUV Lausanne
Lausanne, Canton of Vaud, Switzerland, 1011